EditöryelDeveloping
Hantavirus vaccine could be ready in 100 days, but funding gaps remain
Researchers pursue RNA-based approach following South Korean and Chinese vaccine limitations
Speed:
ℹ️ Browser-based reading · AI studio voice coming soon
PD
Pierre Dubois
· 2 dk okuma
European researchers are pursuing an RNA-based hantavirus vaccine that could be ready within 100 days, though significant funding obstacles persist, according to La Repubblica.
South Korea and China have already developed hantavirus vaccines, but these have shown limited effectiveness. The new approach mirrors the RNA technology used successfully against COVID-19.
However, human trial funding remains unavailable. U.S. biotechnology firm Moderna expressed interest in supporting development, signaling potential progress for the vaccine initiative as Europe confronts rising hantavirus cases.